{
  "ticker": "LLY",
  "target_date": "2025-02-11",
  "actual_date": "2025-02-11",
  "collected_at": "2025-12-08T11:23:29.671812",
  "price": {
    "open": 860.61,
    "high": 867.72,
    "low": 854.13,
    "close": 858.5958251953125,
    "volume": 1944200,
    "change_1d_pct": -0.45,
    "change_7d_pct": 6.65,
    "change_30d_pct": 8.92
  },
  "technicals": {
    "rsi_14": 82.38,
    "sma_20": 795.87,
    "sma_50": 788.74,
    "macd": 23.471,
    "macd_signal": 14.767,
    "macd_histogram": 8.705,
    "bb_upper": 890.62,
    "bb_lower": 701.12,
    "price_vs_sma20_pct": 7.88,
    "price_vs_sma50_pct": 8.86,
    "volume_ratio": 0.47
  },
  "fundamentals": {
    "market_cap": 890705215488,
    "pe_ratio": 48.68124,
    "forward_pe": 43.84749,
    "price_to_book": 37.409042,
    "price_to_sales": 14.990041,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.65,
    "pct_from_52w_low": 59.28
  },
  "macro": {
    "spy": {
      "price": 600.05,
      "change_1d_pct": 0.08,
      "change_7d_pct": 1.26
    },
    "vix": {
      "level": 16.02,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.54
    },
    "dollar_index": {
      "level": 107.96
    },
    "gold": {
      "price": 2912.5
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule",
      "source": "SeekingAlpha",
      "datetime": 1739257758,
      "summary": "Aclaris stock plummets 70% since Sep 2023. Promising ATI-045 results spark debate; past failures fuel skepticism.",
      "url": "https://finnhub.io/api/news?id=02e01fac1aeb6a9f9799855f17e8617b438dd8b0cdd4df9cd2289c11ecf5cec9"
    },
    {
      "headline": "Steady M&A Deals To Begin 2025, Disappointing IPOs So Far",
      "source": "SeekingAlpha",
      "datetime": 1739238000,
      "summary": "A few notable health care deals along with M&A in the AI-adjacent and reshoring themes occurred in January. Read more here.",
      "url": "https://finnhub.io/api/news?id=672b6866755d06c6e531c019654992d06ff098e491e3acc23ca6d5923d328a83"
    },
    {
      "headline": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
      "source": "MarketWatch",
      "datetime": 1739205060,
      "summary": "Eli Lilly & Co. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=c6a7cf79f60c13243ec2675aa972fbd4053f8f793579dd1727b9e81e4b43eac8"
    },
    {
      "headline": "Top 50 High-Quality Dividend Stocks For February 2025",
      "source": "SeekingAlpha",
      "datetime": 1739185095,
      "summary": "Discover 9 top dividend stocks with 10%+ 5-year return potential based on my valuations and in-depth analysis. Click here.",
      "url": "https://finnhub.io/api/news?id=1bce062c7a6827400403ea3d4ea918c03633a1bf87252c135b885948ba7bedef"
    },
    {
      "headline": "Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business",
      "source": "DowJones",
      "datetime": 1739170800,
      "summary": "Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business",
      "url": "https://finnhub.io/api/news?id=a5ee32f60440a697cdbc3b14c047842d2abc05a8c23405c34fefdb99190224e0"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-02-07",
      "description": "xslF345X05/form4-02072025_040211.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000141588925003338/xslF345X05/form4-02072025_040211.xml"
    },
    {
      "form": "8-K",
      "date": "2025-02-06",
      "description": "lly-20250206.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000037/lly-20250206.htm"
    },
    {
      "form": "4",
      "date": "2025-02-04",
      "description": "xslF345X05/wk-form4_1738704486.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000034/xslF345X05/wk-form4_1738704486.xml"
    },
    {
      "form": "4",
      "date": "2025-02-04",
      "description": "xslF345X05/wk-form4_1738704436.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000032/xslF345X05/wk-form4_1738704436.xml"
    },
    {
      "form": "4",
      "date": "2025-02-04",
      "description": "xslF345X05/wk-form4_1738704376.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000030/xslF345X05/wk-form4_1738704376.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}